Breaking News Instant updates and real-time market news.

NVS

Novartis

$90.11

1.105 (1.24%)

09:25
09/03/19
09/03
09:25
09/03/19
09:25

Novartis participates in a conference call with JPMorgan

European Pharma Equity Analyst Vosser holds a conference call with CEO Dr. Vas Narasimhan on September 3 at 10 am hosted by JPMorgan.

  • 03

    Sep

  • 07

    Sep

  • 09

    Sep

  • 19

    Sep

  • 25

    Sep

  • 27

    Sep

NVS Novartis
$90.11

1.105 (1.24%)

07/26/19
ADAM
07/26/19
NO CHANGE
Target $37
ADAM
Buy
Homology Medicines selloff yesterday a buying opportunity, says Canaccord
Canaccord Genuity analyst Michelle Gilson attributes the selloff yesterday in shares of Homology Medicines (FIXX) to a pre-printed, and not peer-reviewed, paper that did not support the company's in vitro data around HR-mediated gene editing. The paper's author, who has previously worked with Sangamo Therapeutics (SGMO) on ZFN-mediated editing, was unable to induce homologous recombination without a nuclease, Gilson tells investors in a research note. "It is tough to understand why an author would choose this route of publication for a study of this nature," says the analyst. She sees "several key differences" between the author's and Homology's in vitro experiments. Further, Homology's technology has been externally validated, allowing Novartis (NVS) and other labs to perform their own in-house experiments using Homology plasmids, Gilson contends. She adds that following this validation, Novartis entered into a collaboration specifically revolving around Homology's gene editing technology for ophthalmic targets. The analyst keeps a Buy rating on Homology Medicines with a $37 price target. Gilson views the selloff in the shares as a buying opportunity into the Phase 1/2 pheNIX data by the end of 2019 for HMI-102 gene therapy in phenylketonuria.
08/10/19
PIPR
08/10/19
NO CHANGE
Target $210
PIPR
Overweight
Amgen wins 'big' in courtroom, Enbrel overhang removed, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and a $210 price target on Amgen's (AMGN) shares following news that the company has won the Enbrel IP litigation with challenger Sandoz. The analyst notes that this challenge could have pulled forward Enbrel's LOE from 2029 to essentially right now, which has been the number 1 concern surrounding the stock. With shares up about 6% on this news, Raymond sees the reaction as appropriate and, while the stock is approaching his target at these levels, he believes shares are likely to grind higher on this removed overhang. Sandoz is a division of Novartis (NVS).
08/12/19
LEHM
08/12/19
NO CHANGE
Target $31
LEHM
Overweight
Coherus should be bought on weakness from Enbrel ruling, says Barclays
Barclays analyst Balaji Prasad recommends buying shares of Coherus Biosciences (CHRS) on any weakness from Amgen's (AMGN) favorable Enbrel patent ruling against Novartis (NVS). Coherus is developing its own Enbrel generic, says the analyst, whose model already factors a launch in Q2 of 2029, following the expiration of the last U.S. Enbrel patent. As such, Prasad is making no change to his estimates following Friday's decision. He remains positive on Coherus and would use any share weakness as an opportunity to add a "fundamentally sound company." Prasad reiterates an Overweight rating on the shares with a $31 price target.
08/13/19
OPCO
08/13/19
NO CHANGE
Target $230
OPCO
Outperform
Amgen price target raised to $230 from $210 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $230 from $210 after the U.S. District Court determined that Sandoz has not met the burden to prove all seven asserted claims invalid and upheld several Enbrel patents. The analyst suspects Sandoz will appeal but views the outcome as highly favorable for Amgen and models flat Enbrel sales until 2021 before declining. Sandoz is a division of Novartis (NVS). Olson reiterates an Outperform rating on Amgen's shares.

TODAY'S FREE FLY STORIES

ALDR

Alder Biopharmaceuticals

$18.50

8.45 (84.08%)

16:40
09/16/19
09/16
16:40
09/16/19
16:40
Upgrade
Alder Biopharmaceuticals rating change  »

Alder upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 21

    Feb

XON

Intrexon

$6.86

0.44 (6.85%)

16:39
09/16/19
09/16
16:39
09/16/19
16:39
Hot Stocks
Intrexon falls after dismissing accountant, notes 'going concern' language »

On September 10, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOP

Shopify

$337.93

-0.77 (-0.23%)

16:38
09/16/19
09/16
16:38
09/16/19
16:38
Syndicate
Shopify files to sell 1.9M Class A subordinate voting shares »

The offering will be led…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

KTOV

Kitov Pharmaceuticals

$0.81

-0.003 (-0.37%)

16:37
09/16/19
09/16
16:37
09/16/19
16:37
Syndicate
Kitov Pharmaceuticals files to sell 2.81M ADSs for holders »

These American Depositary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRQ

Dril-Quip

$55.40

3.36 (6.46%)

16:37
09/16/19
09/16
16:37
09/16/19
16:37
Hot Stocks
Dril-Quip discloses termination of Ca Rong Do project, maintains guidance »

Dril-Quip announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WOW

WideOpenWest

$6.24

0.325 (5.49%)

16:36
09/16/19
09/16
16:36
09/16/19
16:36
Hot Stocks
WOW! names Bill Case CIO, announces departure of CTO Bell »

WOW! Internet, Cable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$44.67

0.75 (1.71%)

16:35
09/16/19
09/16
16:35
09/16/19
16:35
Hot Stocks
Acceleron announces ACE-083 trial does not meet secondary endpoints »

Acceleron announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 04

    Dec

  • 04

    Apr

DMTK

DermTech

$5.80

-0.18 (-3.01%)

16:34
09/16/19
09/16
16:34
09/16/19
16:34
Hot Stocks
DermTech names Kevin Sun CFO »

DermTech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$86.22

0.38 (0.44%)

16:32
09/16/19
09/16
16:32
09/16/19
16:32
Hot Stocks
Leidos awarded $428M ISR support services contract from U.S. Army »

Leidos has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAIC

SAIC

$83.81

-0.39 (-0.46%)

16:31
09/16/19
09/16
16:31
09/16/19
16:31
Hot Stocks
SAIC awarded $85M contract to provide IT services to city of Anaheim, CA »

Science Applications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHC

Encompass Health

16:31
09/16/19
09/16
16:31
09/16/19
16:31
Initiation
Encompass Health initiated  »

Encompass Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 19

    Sep

SEM

Select Medical

$16.97

0.01 (0.06%)

16:31
09/16/19
09/16
16:31
09/16/19
16:31
Initiation
Select Medical initiated  »

Select Medical initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Oct

AMED

Amedisys

$130.73

-2.13 (-1.60%)

16:31
09/16/19
09/16
16:31
09/16/19
16:31
Initiation
Amedisys initiated  »

Amedisys initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 13

    Nov

16:30
09/16/19
09/16
16:30
09/16/19
16:30
Options
Preliminary option volume of 19.0M today »

Preliminary option volume…

CME

CME Group

$207.01

1.26 (0.61%)

16:29
09/16/19
09/16
16:29
09/16/19
16:29
Initiation
CME Group initiated  »

CME Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

PBH

Prestige Brands

$34.97

-1.03 (-2.86%)

16:27
09/16/19
09/16
16:27
09/16/19
16:27
Conference/Events
Prestige Brands management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

CBOE

Cboe Global Markets

$110.75

-0.11 (-0.10%)

16:27
09/16/19
09/16
16:27
09/16/19
16:27
Initiation
Cboe Global Markets initiated  »

Cboe Global Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNKO

Funko

$27.86

0.47 (1.72%)

16:26
09/16/19
09/16
16:26
09/16/19
16:26
Syndicate
Funko files to sell 4M shares of Class A common stock for holders »

J.P. Morgan is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CURO

Curo Group

$15.28

-0.045 (-0.29%)

16:25
09/16/19
09/16
16:25
09/16/19
16:25
Conference/Events
Curo Group management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 20

    Sep

  • 13

    Nov

ICE

IntercontinentalExchange

$91.88

1.05 (1.16%)

16:25
09/16/19
09/16
16:25
09/16/19
16:25
Initiation
IntercontinentalExchange initiated  »

IntercontinentalExchange…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

CME

CME Group

$207.01

1.26 (0.61%)

16:23
09/16/19
09/16
16:23
09/16/19
16:23
Conference/Events
CME Group management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

USB

U.S. Bancorp

$55.86

-0.21 (-0.37%)

16:23
09/16/19
09/16
16:23
09/16/19
16:23
Hot Stocks
U.S. Bancorp director David O'Maley sells over $565K in shares of company stock »

U.S. Bancorp director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

FDX

FedEx

$173.64

-0.49 (-0.28%)

16:22
09/16/19
09/16
16:22
09/16/19
16:22
Hot Stocks
FedEx to increase shipping rates, surcharges in January 2020 »

FedEx Express, FedEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

FDX

FedEx

$173.64

-0.49 (-0.28%)

16:21
09/16/19
09/16
16:21
09/16/19
16:21
Hot Stocks
FedEx announces no additional residential surcharges for holiday season »

FedEx Corp. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
09/16/19
09/16
16:20
09/16/19
16:20
Options
Closing CBOE SPX and VIX Index summary for September 16th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.